TY - JOUR
T1 - The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease
AU - Kieburtz, Karl
AU - McDermott, M.
AU - Como, P.
AU - Growdon, J.
AU - Brady, J.
AU - Carter, J.
AU - Huber, S.
AU - Kanigan, B.
AU - Landow, E.
AU - Rudolph, A.
AU - Saint-Cyr, J.
AU - Stern, Y.
AU - Tennis, M.
AU - Thelen, J.
AU - Shoulson, I.
PY - 1994/9
Y1 - 1994/9
N2 - We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.
AB - We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.
UR - http://www.scopus.com/inward/record.url?scp=0028025072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028025072&partnerID=8YFLogxK
U2 - 10.1212/wnl.44.9.1756
DO - 10.1212/wnl.44.9.1756
M3 - Article
C2 - 7936311
AN - SCOPUS:0028025072
SN - 0028-3878
VL - 44
SP - 1756
EP - 1759
JO - Neurology
JF - Neurology
IS - 9
ER -